Pancreatic Cancer
The research activity centres on pancreatic ductal adenocarcinoma, with interest in treatment strategies for stage I-III disease and the role of pre-operative chemotherapy in managing resectable and locally advanced presentations.
- Pancreatic ductal adenocarcinoma
- Stage I-III pancreatic cancer
- Pre-operative chemotherapy
The sponsor’s funded research is focused on clinical questions relevant to disease control and treatment selection in pancreatic cancer.
Systemic Therapy for Pancreatic Malignancy
Clinical interest includes multi-agent chemotherapy approaches used in pancreatic cancer, with attention to established regimens such as mFOLFIRINOX and PAXG.
- mFOLFIRINOX
- PAXG regimen
- Combination chemotherapy
These areas reflect a therapeutic focus on optimizing systemic treatment options for patients with pancreatic ductal adenocarcinoma.
Neoadjuvant Treatment Strategy
Research activity also covers the use of neoadjuvant therapy before surgery, with interest in how treatment duration and regimen choice affect outcomes in pancreatic cancer.
- Neoadjuvant therapy
- Short-course chemotherapy
- Long-course chemotherapy
This area is closely linked to treatment planning for patients considered for curative-intent management of PDAC.
Outcome-Oriented Oncology Research
The sponsored trial activity is directed toward clinical outcomes in oncology, with particular attention to event-free survival as a measure of treatment effectiveness in pancreatic cancer.
- Event-free survival
- Treatment efficacy
- Comparative oncology
Interest in outcome assessment supports refinement of therapeutic choices for pancreatic ductal adenocarcinoma.
